{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-025427","form_type":"8-K","ticker":"APVO","cik":"0001671584","company_name":"Aptevo Therapeutics Inc.","filed_at":"2024-03-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.053564+00:00","generated_at":"2026-06-05T03:50:24.789733+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Aptevo reports 2023 net loss of $17.4M; cash $16.9M; AML trial plan announced","bullets":["Net loss $17.4M ($1.42/share) vs 2022 net income $8.0M ($1.57/share); cash $16.9M at Dec 31, 2023.","APVO436 Phase 1b/2 frontline AML trial to start 1H24; interim data expected late 2H24; prior combo showed 91% clinical benefit rate.","ALG.APV-527 Phase 1 solid tumor trial enrolling; interim results expected 1H24.","R&D expenses fell to $17.1M (down $0.8M); G&A fell to $11.8M (down $2.1M); $9.65M gain from asset sale."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-025427","json":"https://secwatch.observer/filing/0000950170-24-025427.json","markdown":"https://secwatch.observer/filing/0000950170-24-025427.md","text":"https://secwatch.observer/filing/0000950170-24-025427.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671584/000095017024025427/0000950170-24-025427-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671584/000095017024025427/apvo-20240305.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T03:50:24.789733+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"79024fd311d00dcb4156f8ffef344a34a7153699","claim":"Aptevo Therapeutics Inc. reported financial results for year ended December 31, 2023.","evidence_excerpt":"Aptevo Therapeutics Inc. (the “Company”) issued a press release announcing its financial results for the period ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1671584/000095017024025427/0000950170-24-025427-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}